Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Mesoblast Announces Phase 3 Trial of Cell Therapy in Chronic Heart Failure Completes Recruitment

07 Jan 2019  |  10:57:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment

Mesoblast announced that it has completed patient recruitment in the events-driven Phase 3 trial of its product candidate Revascor (MPC-150-IM) for advanced chronic heart failure. The Phase 3 trial is evaluating whether Revascor reduces recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE) and prevents or delays terminal cardiac events (TCEs), defined as cardiovascular death, heart transplant or placement of an artificial device, over at least 12 months. In a previous Phase 2 trial, a single dose of Revascor prevented any TCEs or hospitalization events over three years in a similar patient cohort. There are over 8m patients with heart failure in the US alone, with 15-20% refractory to all existing medicines.

Please click here for full details

See more ASX300 News Announcements